Among all diagnosed cases of invasive breast cancer, approximately 15–20% are triple-negative breast cancer (TNBC) [1], a cancer type without estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Here, ESR1 is linked to invasive breast carcinoma.